Abstract
AveXis, the gene-therapy firm that Novartis acquired last year, plans to buy AstraZeneca’s biologics manufacturing plant in Longmont, Colorado. In January, AstraZeneca announced it would close the Longmont plant and a nearby site in Boulder, laying off 210 employees. AveXis says it will offer jobs to about 150 of those employees. AveXis anticipates US Food and Drug Administration approval in May of Zolgensma, which would be the second viral gene therapy approved in the US. AveXis already has gene-therapy manufacturing plants in Illinois, North Carolina, and California.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
